Dudediligence.

Acumen Pharmaceuticals, Inc

ABOSNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

72.3M

on 2026-06-30, from 60.1M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

20M40M60MMar2024JunSepDecMar2025JunSepDecMar2026$3.30Jun

Newest

None

No S-3 or F-3 shelf on file in the last 30 months.

$50.0M

BofA Securities, agreement of 2025-11-13. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-12 is not read yet.

Cash

4.8 quarters

$110.2M on 2026-06-30 ÷ $22.9M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-03-13Private placement10,833,331$3.30$35.8M8-K ↗